leading glp-1 treatments for diabetes 2025 Pipeline Update: August - Prime Therapeutics Top Obesity and Diabetes Medications

As a result of the court ruling, this marks the end of the Food and Drug Administrations (FDA) enforcement discretion as follows: Small-scale compounders (i.e., 503A facilities), licensed by individual states and physician compounding, must stop producing compounded tirzepatide immediately

GLP-1 medications are not for those with a history of Medullary Thyroid Carcinoma or MEN 2

Underlying cardiovascular disease: Many patients prescribed GLP-1 medications have cardiovascular risk factors or established heart disease

F., Collins, J

Theyre not licensed nationallythey employ providers with licenses in multiple states and match you to someone licensed where you are

Fiber-rich fruits, vegetables, and whole grains provide essential fuel for the good bacteria in your gut